Agencies, 08 May: Drugs Controller General of India para DRDO para bona anti-COVID oral drug te emergency use nemite manishe. Etu moderate to severe coronavirus patients ke adjunct therapy hisab te jolabo koise. Etu khobor toh Saturday te defence ministry para janaideya laga ase. Drug 2-deoxy-D-glucose (2-DG) laga clinical trials te hospitalised patients laga joldi recovery nemite motob powa aro supplemental oxygen dependence nama dekhaise koise.
Drug toh Defence Research and Development Organisation (DRDO) laga ekta leading laboratory, Institute of Nuclear Medicine and Allied Sciences (INMAS) para Dr Reddy’s Laboratories in Hyderabad logote melikena bona laga ase. 2-DG toh packet te powder form te ahishe aro paani te dissolve korikena khabo koise.
Ministry para statement te koise, “May 01 te, DCGI para etu drug laga emergency use nemite permission gara korise, moderate to severe COVID-19 patients te adjunct therapy hisab te. Generic molecule howa aro glucose nesana nemite, etu toh sosta para olabole paribo aro desh te besi thaka bonabole paribo koise”.
Ministry koise, etu para virus infected cells te jama kori aro viral synthesis aro energy production te rokhai kena virus growth te rokhai koise. Etu drug para virally-infected cells jama kora nemite unique bonaise koise.
Add Comment